Handunnetti S M, Gunewardena D M, Pathirana P P, Ekanayake K, Weerasinghe S, Mendis K N
Department of Parasitology, Faculty of Medicine, University of Colombo, Sri Lanka.
Trans R Soc Trop Med Hyg. 1996 Sep-Oct;90(5):563-7. doi: 10.1016/s0035-9203(96)90325-9.
This paper reports on the features of recrudescent infections of chloroquine-resistant Plasmodium falciparum (CQRPf) malaria from a study in vivo of patients from a malaria endemic (n = 527) and non-endemic (n = 129) region of Sri Lanka where the incidence of RI resistance was 30% and 55%, respectively. In both groups of patients, the recrudescent infections which emerged after treatment of the primary infection with chloroquine (CQ) and primaquine had significantly lower peripheral parasitaemia (0.036% and 0.108% in endemic and non-endemic patients, respectively) compared to their primary infections (mean parasitaemia 0.13% and 0.49%; P = 0.021 and 0.002, respectively). The recrudescences of CQ resistant infections also gave rise to clinical disease of markedly reduced severity (average clinical scores of 10.1 and 8.2) compared to their primary infections (average clinical scores of 12.4 and 12.3; P = 0.003 and 0.001, respectively, in endemic and non-endemic patients). CQ resistant recrudescent infections therefore had a lower probability of being diagnosed and treated. In endemic patients, a higher proportion of CQRPf infections (57%) had gametocytaemia compared to the chloroquine sensitive ones (29%) (P = 0.014, chi 2 = 5.96) and were significantly more infective to mosquitoes (P = 0.047). these findings imply that, in areas where CQ resistance is prevalent, the continued use of the drug may confer a survival and propagation advantage on resistant parasites and favour the rapid expansion of their reservoir. In support of this, we also present epidemiological evidence showing that, in endemic areas, the proportion of P. falciparum patients carrying gametocytes has increased significantly since the emergence of chloroquine resistance. These findings are relevant to the management of drug resistance and malaria control in countries where P.falciparum is only partially resistant to CQ.
本文报告了来自斯里兰卡疟疾流行地区(n = 527)和非流行地区(n = 129)的患者体内耐氯喹恶性疟原虫(CQRPf)疟疾再燃感染的特征,其中再燃感染耐药率在流行区和非流行区分别为30%和55%。在两组患者中,用氯喹(CQ)和伯氨喹治疗原发性感染后出现的再燃感染,其外周血寄生虫血症明显低于原发性感染(流行区和非流行区患者分别为0.036%和0.108%),原发性感染的平均寄生虫血症分别为0.13%和0.49%;P值分别为0.021和0.002)。与原发性感染相比,耐氯喹感染的再燃也引发了严重程度明显降低的临床疾病(平均临床评分分别为10.1和8.2),原发性感染的平均临床评分分别为12.4和12.3;流行区和非流行区患者的P值分别为0.003和0.001)。因此,耐氯喹再燃感染被诊断和治疗的可能性较低。在流行区患者中,与氯喹敏感感染(29%)相比,耐氯喹恶性疟原虫感染出现配子体血症的比例更高(57%)(P = 0.014,卡方 = 5.96),并且对蚊子的传染性明显更强(P = 0.047)。这些发现表明,在氯喹耐药普遍存在的地区,持续使用该药物可能会使耐药寄生虫具有生存和繁殖优势,并有利于其储存库的迅速扩大。为此,我们还提供了流行病学证据,表明在流行区,自氯喹耐药出现以来,携带配子体的恶性疟原虫患者比例显著增加。这些发现与恶性疟原虫仅对氯喹部分耐药的国家的耐药管理和疟疾控制相关。